The first Reglan lawsuit involving tardive dyskinesia was filed more than 20 years ago, and more than 70 cases have been filed in state and federal courts throughout the United States since then. In February of 2009, the U.S. Judicial Panel on Multidistrict Litigation considered a petition to centralize and consolidate 11 currently pending Reglan tardive dyskinesia lawsuits before one judge for pretrial litigation to avoid duplicate discovery, inconsistent rulings and serve the convenience of the parties, attorneys and witnesses. Potential cases are still being reviewed by Reglan lawyers and individual lawsuits will proceed in various courts throughout the United States. In June of 2009, it was decided that lawsuits would not progress into a Multidistrict Litigation.
Reglan, one of the trade names for the medical drug metoclopramide, is classified as a dopamine antagonist. In order to understand the side effects of Reglan, it is helpful to learn how the brain and nervous system work together in order to control bodily functions and the role of dopamine. Metoclopramide, a generic form of Reglan, became popular in the late 1990s after its predecessor, Cisapride, was found to cause serious side effects. Unfortunately for many patients who had already begun to take metoclopramide, a study published in 2004 found the medication could cause a movement disorder known as tardive dyskinesia.
Persons suffering from tardive dyskinesia exhibit symptoms, such as: involuntary movements, twitching or shaking, rapid limb movement, facial grimacing, twit or movement, lip pursing, smacking, and involuntary tongue licking. The symptoms are irreversible in many cases and in others, may only lessen over time, but will never fully subside. In response, the FDA now mandates all manufacturers of the drug Reglan to carry a black box warning on all Reglan products. Nationwide, individuals suffering from the adverse effects of Reglan are contacting experienced Reglan lawyers to ensure proper representation.
No comments:
Post a Comment